Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

NCT01374425 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: 5-Fluorouracil
DRUG: Bevacizumab
DRUG: Irinotecan
DRUG: Leucovorin
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

Genentech, Inc.